Titre:
  • Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Auteur:Kudo, Masatoshi; Finn, Richard R.S.; Edeline, Julien; Cattan, Stéphane; Ogasawara, Sadahisa; Palmer, Daniel D.H.; Verslype, Chris; Zagonel, Vittorina; Fartoux, Laetitia; Vogel, Arndt; Sarker, Debashis; Verset, Gontran; Chan, Stephen Lam; Knox, Jennifer; Daniele, Bruno; Yau, Thomas; Gurary, Ellen E.B.; Siegel, Abby A.B.; Wang, Anran; Cheng, Ann Lii; Zhu, Andrew Xiuxuan
Informations sur la publication:European journal of cancer, 167, page (1-12)
Statut de publication:Publié, 2022-05
Sujet CREF:Cancérologie
Mots-clés:Advanced hepatocellular carcinoma
Anti-PD-1
Long-term treatment
Pembrolizumab
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:doi/10.1016/j.ejca.2022.02.009
info:pii/S0959804922000843
info:scp/85127171092
info:pmid/35364421